Skip to main content
SpringerLink
Log in

Erythropoiesis-Stimulating Agent Therapy

  • Chapter
  • First Online:
Pocket Reference to Renal Anemia

  • 920 Accesses

Abstract

Erythropoiesis-stimulating agents remain the cornerstone of CKD anemia management. They were introduced in 1990 and transformed the management of anemia in dialysis patients, many of whom were transfusion-dependent and iron overloaded.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 49.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther. 1991;50:702-712.

    Google Scholar 

  2. Retacrit [package insert]. Warwickshire, UK: Hospira; 2010.

    Google Scholar 

  3. Binocrit [package insert]. Kundl, Austria: Sandoz; 2010.

    Google Scholar 

  4. Eporatio [package insert]. Ulm, Germany: Merckle Biotec; 2009.

    Google Scholar 

  5. Macdougall IC, Ashenden M. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis. 2009;16:117-130.

    Google Scholar 

  6. Aranesp [package insert]. Thousand Oaks, CA: Amgen; 2012.

    Google Scholar 

  7. Mircera [package insert]. Welwyn Garden City, UK: Hoffmann-La Roche; 2007.

    Google Scholar 

  8. Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol. 2006;34:1303-1311.

    Google Scholar 

  9. Macdougall IC, Provenzano R, Sharma A, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med. 2013;368:320-332.

    Google Scholar 

  10. Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med. 2013;368:307-319.

    Google Scholar 

  11. Macdougall IC, Rossert J, Casadevall N, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009;361:1848-1855.

    Google Scholar 

  12. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590.

    Google Scholar 

  13. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-2084.

    Google Scholar 

  14. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098.

    Google Scholar 

  15. Pfeffer MA, Burdmann EA, Chen C-Y, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-2032.

    Google Scholar 

  16. National Kidney Foundation. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:v-335.

    Google Scholar 

  17. National Kidney Foundation. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471-530.

    Google Scholar 

  18. National Institute for Health and Clinical Excellence. Anaemia management in people with chronic kidney disease. http://guidance.nice.org.uk/CG114. Updated November 2012. Accessed February 6, 2013.

  19. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914-924.

    Google Scholar 

  20. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260.

    Google Scholar 

  21. Elliott S, Busse L, Bass MB, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood. 2006;107:1892-1895.

    Google Scholar 

  22. Fandrey J. Erythropoietin receptors on tumor cells: what do they mean? Oncologist. 2008;13(suppl 3):16-20.

    Google Scholar 

  23. Swift S, Ellison AR, Kassner P, et al. Absence of functional EpoR expression in human tumor cell lines. Blood. 2010;115:4254-4263.

    Google Scholar 

  24. Sinclair AM, Coxon A, McCaffery I, et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood. 2010;115:4264-4272.

    Google Scholar 

  25. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16:2180-2189.

    Google Scholar 

  26. Skali H, Parving HH, Parfrey PS, et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011;124:2903-2908.

    Google Scholar 

  27. Vaziri ND, Zhou XJ. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant. 2009;24:1082-1088.

    Google Scholar 

  28. Labonia WD. L-Carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis. 1995;26:757-764.

    Google Scholar 

  29. Tarng DC, Huang TP. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant. 1998;13:2867-2872.

    Google Scholar 

  30. Albitar S, Genin R, Fen-Chong M, et al. High-dose alfacalcidol improves anaemia in patients on haemodialysis. Nephrol Dial Transplant. 1997;12:514-518.

    Google Scholar 

  31. Ballal SH, Domoto DT, Polack DC, et al. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis. 1991;17:29-33.

    Google Scholar 

  32. Pronai W, Riegler-Keil M, Silberbauer K, Stockenhuber F. Folic acid supplementation improves erythropoietin response. Nephron. 1995;71:395-400.

    Google Scholar 

  33. Brox AG, Zhang F, Guyda H, Gagnon RF. Subtherapeutic erythropoietin and insulin-like growth factor-1 correct the anemia of chronic renal failure in the mouse. Kidney Int. 1996;50:937-943.

    Google Scholar 

  34. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol. 2004;15:1877-1882.

    Google Scholar 

  35. Johnson DW, Hawley CM, Rosser B, et al. Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. BMC Nephrol. 2008;9:8.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Renal Medicine, King’s College Hospital, London, UK

    Iain C. Macdougall

Authors
  1. Iain C. Macdougall
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Healthcare

About this chapter

Cite this chapter

Macdougall, I.C. (2013). Erythropoiesis-Stimulating Agent Therapy. In: Pocket Reference to Renal Anemia. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-48-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-907673-48-1_6

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-908517-74-6

  • Online ISBN: 978-1-907673-48-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation